GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2009

China Buys $12.8M of Hepatitis A Vaccine from Sinovac

China Buys $12.8M  of Hepatitis A Vaccine from Sinovac

Chinese government purchases hepatitis A vaccine from Sinovac

  • The Chinese Ministry of Public Health placed an ¥87 million ($12.8 million) order for Sinovac Biotech's inactivated hepatitis A vaccine, Healive. The vaccine will be used in a campaign targeted at children from 18 months to 12 years in nine provinces across the country, says the company.

    Sinovac is a China-based biopharmaceutical company focused on producing and developing vaccines for use against human infectious disease. In 2008, Sinovac collaborated with the Ministry of Health to provide hepatitis A vaccine to people living in the Sichuan province who were affected by the major earthquake there. Sinovac says that it recently completed expansion on a filing and packaging plant and that its annual capacity is now 20 million doses.

    "We are very pleased to have established a public market for our inactivated hepatitis A vaccine, Healive, through this supply agreement with the MOH, as we are focusing our efforts in 2009 on both the public and private pay markets," says Weidong Yin, chairman, president, and CEO of Sinovac.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?